Ortiza, Charydel .
HRN: 21-51-43 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/27/2022
CO-AMOXICLAV 625MG (TAB)
06/27/2022
07/04/2022
PO
625
BId
Lacerated Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes